SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-031893
Filing Date
2022-02-09
Accepted
2022-02-09 08:05:04
Documents
14
Period of Report
2022-02-03
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d222596d8k.htm   iXBRL 8-K 24684
2 EX-99.1 d222596dex991.htm EX-99.1 9372
6 GRAPHIC g222596g0209020650424.jpg GRAPHIC 5440
  Complete submission text file 0001193125-22-031893.txt   171248

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cadl-20220203.xsd EX-101.SCH 2859
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cadl-20220203_lab.xml EX-101.LAB 18737
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cadl-20220203_pre.xml EX-101.PRE 11709
8 EXTRACTED XBRL INSTANCE DOCUMENT d222596d8k_htm.xml XML 3548
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

IRS No.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40629 | Film No.: 22603852
SIC: 2836 Biological Products, (No Diagnostic Substances)